GO:0140972 negative regulation of AIM2 inflammasome complex assembly: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140972 describes any process that stops, prevents, or reduces the frequency, rate, or extent of AIM2 inflammasome complex assembly.
• The AIM2 inflammasome is a cytosolic innate immune platform that detects double-stranded DNA and triggers caspase-1 activation, IL-1beta and IL-18 maturation, and pyroptotic cell death.
• Negative regulation of AIM2 inflammasome assembly is essential to prevent excessive inflammation and autoinflammatory disease.
• Multiple cellular mechanisms, including autophagy, protein degradation, and decoy proteins, can inhibit AIM2 inflammasome assembly.
• Dysregulation of AIM2 inflammasome assembly is linked to autoinflammatory disorders, cancer, and chronic inflammatory diseases.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of negative regulators of AIM2 inflammasome assembly.
Description
The AIM2 inflammasome is a multiprotein cytosolic complex that senses double-stranded DNA from pathogens or damaged host cells and initiates a potent inflammatory response. Assembly of this complex is a tightly controlled process, and its dysregulation contributes to a range of human diseases, including autoinflammatory syndromes and cancer. The Gene Ontology term GO:0140972, negative regulation of AIM2 inflammasome complex assembly, captures the biological processes that restrain this assembly to maintain immune homeostasis. Understanding these negative regulatory mechanisms is critical for researchers studying innate immunity, inflammation, and therapeutic intervention strategies. This article provides a comprehensive overview of GO:0140972, including its definition, key genes, molecular mechanisms, disease relevance, and state-of-the-art research methods.
negative regulation of AIM2 inflammasome complex assembly At A Glance
| GO ID | GO:0140972 |
|---|---|
| GO term | negative regulation of AIM2 inflammasome complex assembly |
| Ontology | biological_process |
| Synonym | none |
| Major function | Inhibition of AIM2 inflammasome complex formation |
| Biological context | Innate immunity, inflammation, host defense |
| Key regulators | Autophagy proteins, decoy proteins, ubiquitin ligases |
| Disease relevance | Autoinflammatory disorders, cancer, chronic inflammation |
What Is GO:0140972?
GO:0140972, negative regulation of AIM2 inflammasome complex assembly, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of AIM2 inflammasome complex assembly. In other words, it encompasses all cellular and molecular events that inhibit the formation of the AIM2 inflammasome, a cytosolic DNA-sensing platform that activates inflammatory caspases. This regulation is crucial for preventing uncontrolled inflammation and maintaining immune balance.
Why Is negative regulation of AIM2 inflammasome complex assembly Important in Cell Biology?
Negative regulation of AIM2 inflammasome complex assembly is vital for preventing excessive inflammatory responses that can damage host tissues. The AIM2 inflammasome detects cytosolic DNA and triggers caspase-1 activation, leading to the release of pro-inflammatory cytokines IL-1beta and IL-18 and pyroptotic cell death. Without proper negative regulation, aberrant AIM2 inflammasome activation contributes to autoinflammatory diseases, such as psoriasis and arthritis, as well as to cancer progression and chronic inflammatory conditions. Therefore, understanding the mechanisms that restrain AIM2 inflammasome assembly offers potential therapeutic targets for modulating inflammation.
• Prevents autoinflammatory diseases caused by excessive IL-1beta and IL-18 signaling.
• Maintains immune homeostasis by avoiding uncontrolled pyroptosis.
• Limits tissue damage during infections by balancing protective and pathological inflammation.
• Modulates cancer immunity, as AIM2 inflammasome activity can influence tumor progression.
• Provides targets for anti-inflammatory drug development.
• Helps understand crosstalk between innate and adaptive immunity.
• Relevant to diseases such as psoriasis, arthritis, and colitis.
• Guides development of CRISPR-based models to study inflammatory pathways.
What Happens During negative regulation of AIM2 inflammasome complex assembly?
Recognition of AIM2 by negative regulators
In simple terms: Certain proteins recognize AIM2 and block it from assembling into the inflammasome.
Negative regulation of AIM2 inflammasome assembly often begins with the recognition of AIM2 or its adaptor ASC by inhibitory proteins. For example, the autophagy protein p62/SQSTM1 can target AIM2 for degradation, preventing its oligomerization. Other decoy proteins may bind to AIM2 and sequester it from the assembly site.
Inhibition of AIM2 oligomerization
In simple terms: Stopping AIM2 molecules from clustering together prevents inflammasome formation.
AIM2 must oligomerize upon DNA binding to recruit ASC and procaspase-1. Negative regulators can interfere with this step by binding to AIM2's HIN domain or by modifying its conformation. For instance, phosphorylation of AIM2 by certain kinases can disrupt its oligomerization.
Degradation of AIM2 or inflammasome components
In simple terms: Cells can destroy AIM2 or its partners to stop inflammasome assembly.
Ubiquitination and subsequent proteasomal degradation of AIM2 or ASC is a major negative regulatory mechanism. E3 ubiquitin ligases such as TRIM11 have been shown to promote AIM2 degradation, thereby inhibiting inflammasome assembly. Autophagy also contributes by delivering AIM2 to lysosomes for degradation.
Interference with ASC speck formation
In simple terms: Blocking the formation of ASC specks prevents the inflammasome from signaling.
ASC speck formation is a hallmark of inflammasome assembly. Negative regulators can inhibit ASC polymerization or promote its disassembly. For example, the protein POP1 (PYD-only protein 1) can bind to ASC and prevent its nucleation, thus blocking AIM2 inflammasome assembly.
Regulation by post-translational modifications
In simple terms: Chemical tags on AIM2 or ASC can turn off inflammasome assembly.
Post-translational modifications such as phosphorylation, ubiquitination, and SUMOylation play critical roles in negative regulation. These modifications can alter protein-protein interactions, stability, or localization, thereby preventing AIM2 inflammasome assembly. For instance, phosphorylation of AIM2 at specific residues by TBK1 has been reported to inhibit its function.
Key Genes Involved in GO:0140972 negative regulation of AIM2 inflammasome complex assembly
The following genes and proteins are key players in the negative regulation of AIM2 inflammasome complex assembly, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AIM2 | Cytosolic DNA sensor; forms inflammasome | Target for negative regulation; knockout models available |
| ASC (PYCARD) | Adaptor protein; forms specks | Essential for inflammasome assembly; regulated by decoys |
| CASP1 | Inflammatory caspase; executes pyroptosis | Effector of AIM2 inflammasome; regulated by inhibitors |
| SQSTM1 (p62) | Autophagy receptor; targets AIM2 for degradation | Negative regulator via selective autophagy |
| TRIM11 | E3 ubiquitin ligase; ubiquitinates AIM2 | Promotes AIM2 degradation; potential therapeutic target |
| POP1 | PYD-only decoy protein; binds ASC | Inhibits ASC nucleation; blocks inflammasome assembly |
| TBK1 | Kinase; phosphorylates AIM2 | Negative regulation by phosphorylation |
| IKKalpha | Kinase; phosphorylates AIM2 | Inhibits AIM2 inflammasome assembly |
| NLRC3 | NLR family member; inhibits inflammasome | Negative regulator of AIM2 and other inflammasomes |
| NLRP12 | NLR family member; inhibits inflammasome | Negative regulator of AIM2 inflammasome |
| CARD16 | Caspase recruitment domain protein; decoy | Inhibits caspase-1 activation by AIM2 inflammasome |
| CARD17 | Caspase recruitment domain protein; decoy | Inhibits caspase-1 activation |
| CARD18 | Caspase recruitment domain protein; decoy | Inhibits caspase-1 activation |
| PYDC1 | PYD-only protein; decoy for ASC | Inhibits AIM2 inflammasome assembly |
| PYDC2 | PYD-only protein; decoy for ASC | Inhibits AIM2 inflammasome assembly |
| TRIM21 | E3 ubiquitin ligase; ubiquitinates AIM2 | Promotes AIM2 degradation |
| RNF144B | E3 ubiquitin ligase; ubiquitinates AIM2 | Negative regulator of AIM2 inflammasome |
| USP50 | Deubiquitinase; removes ubiquitin from AIM2 | May stabilize AIM2; context-dependent |
How Is negative regulation of AIM2 inflammasome complex assembly Regulated?
Negative regulation of AIM2 inflammasome complex assembly is controlled by multiple cellular pathways. Autophagy, a lysosomal degradation pathway, can target AIM2 and inflammasome components for destruction, thereby limiting inflammasome activity. Post-translational modifications, including phosphorylation by TBK1 and IKKalpha, can directly inhibit AIM2 function. Additionally, decoy proteins such as POP1 and CARD-only proteins compete with AIM2 or ASC for binding partners, preventing assembly. The expression of these negative regulators is often induced by inflammatory stimuli, creating a feedback loop to prevent excessive inflammation. Understanding how these regulatory mechanisms are themselves controlled is an active area of research.
negative regulation of AIM2 inflammasome complex assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AIM2 | Psoriasis, arthritis | Knockout mice, point mutant knock-in |
| ASC | Autoinflammatory syndromes | Knockout cell lines, overexpression |
| CASP1 | Inflammatory bowel disease | Knockout mice, point mutation |
| SQSTM1 | Crohn's disease | Knockout mice, overexpression |
| TRIM11 | Cancer, inflammation | Knockout cell lines, knock-in |
Autoinflammatory diseases
Dysregulated AIM2 inflammasome assembly leads to excessive IL-1beta and IL-18 production, contributing to autoinflammatory diseases such as psoriasis, arthritis, and periodic fever syndromes. Negative regulators of AIM2 inflammasome assembly are therefore potential therapeutic targets.
Cancer
AIM2 inflammasome activity can have dual roles in cancer, promoting antitumor immunity or driving chronic inflammation that supports tumor growth. Negative regulation of AIM2 inflammasome assembly may influence tumor progression and response to immunotherapy.
Chronic inflammatory diseases
In conditions like colitis and atherosclerosis, persistent AIM2 inflammasome activation exacerbates tissue damage. Enhancing negative regulatory mechanisms could mitigate inflammation.
From negative regulation of AIM2 inflammasome complex assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate AIM2 inflammasome assembly? | Knockout cell line (e.g., THP-1) followed by AIM2 inflammasome activation assays |
| Does a specific mutation in AIM2 affect its regulation? | Point mutation knock-in using CRISPR in cell lines |
| Does protein X interact with AIM2? | Tagged knock-in (e.g., GFP or FLAG) for co-immunoprecipitation |
| Does overexpression of gene Y inhibit AIM2 inflammasome? | Overexpression cell lines via lentiviral transduction |
| What is the role of gene Z in vivo? | Knockout mice with AIM2 inflammasome activation models |
| Can we screen for novel negative regulators? | CRISPR library screening with inflammasome readouts |
How to Study the negative regulation of AIM2 inflammasome complex assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene loss effects on inflammasome assembly | Identify negative regulators |
| Proteomics | Protein interactions and modifications | Map AIM2 interactome |
| Fluorescence microscopy | ASC speck formation | Visualize inflammasome assembly |
| ELISA | IL-1beta and IL-18 secretion | Quantify inflammasome activity |
| Western blot | Caspase-1 cleavage | Assess inflammasome activation |
| Flow cytometry | Pyroptosis and cytokine production | Measure cell death and inflammation |
| RNA-seq | Transcriptional changes | Identify pathways regulated by negative regulators |
| Co-immunoprecipitation | Protein-protein interactions | Validate binding of negative regulators |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss enhances AIM2 inflammasome assembly, revealing negative regulators. These screens typically use readouts such as caspase-1 activation or IL-1beta secretion.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify proteins that interact with AIM2 or ASC, uncovering potential negative regulators. Proximity labeling approaches such as BioID can map the AIM2 interactome in living cells.
Imaging of ASC specks
Fluorescence microscopy can visualize ASC speck formation, a readout of AIM2 inflammasome assembly. High-content imaging allows quantification of speck formation in response to negative regulators.
Cytokine assays
ELISA or cytokine bead arrays measure IL-1beta and IL-18 release, reflecting AIM2 inflammasome activity. These assays are used to assess the impact of negative regulators.
How CRISPR Can Be Used to Study GO:0140972 negative regulation of AIM2 inflammasome complex assembly
Knockout
CRISPR knockout of candidate negative regulators can be used to assess their role in AIM2 inflammasome assembly. For example, knocking out SQSTM1 or TRIM11 may enhance inflammasome activation, confirming their inhibitory function.
Point Mutation
Point mutations can be introduced into AIM2 or its regulators to study specific residues required for negative regulation. For instance, mutating phosphorylation sites on AIM2 can reveal their importance in inhibiting assembly.
Knock-in
Knock-in of tagged versions of AIM2 or ASC (e.g., GFP, FLAG) allows visualization and purification of inflammasome components. This enables detailed biochemical and imaging studies of negative regulation.
Overexpression
Overexpression of suspected negative regulators can test their ability to inhibit AIM2 inflammasome assembly. This approach is useful for gain-of-function studies and for validating screening hits.
How EDITGENE Supports negative regulation of AIM2 inflammasome complex assembly Research
Researchers studying negative regulation of AIM2 inflammasome complex assembly-related genes often need to determine whether a candidate gene is causally involved in restraining inflammasome activation. EDITGENE provides comprehensive CRISPR-based services to accelerate this research, from knockout and point mutation models to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of AIM2 inflammasome complex assembly research.
Frequently Asked Questions About negative regulation of AIM2 inflammasome complex assembly
What is GO:0140972?
GO:0140972 is the Gene Ontology term for negative regulation of AIM2 inflammasome complex assembly, describing any process that stops, prevents, or reduces the assembly of the AIM2 inflammasome.
What is the AIM2 inflammasome?
The AIM2 inflammasome is a cytosolic multiprotein complex that detects double-stranded DNA and activates inflammatory caspases, leading to cytokine release and pyroptosis.
What genes are involved in negative regulation of AIM2 inflammasome complex assembly?
Key genes include SQSTM1 (p62), TRIM11, POP1, TBK1, IKKalpha, NLRC3, NLRP12, CARD16, CARD17, CARD18, PYDC1, PYDC2, TRIM21, and RNF144B.
Why is negative regulation of AIM2 inflammasome assembly important?
It prevents excessive inflammation and autoinflammatory diseases by restraining AIM2 inflammasome activity.
What diseases are associated with AIM2 inflammasome dysregulation?
Diseases include psoriasis, arthritis, inflammatory bowel disease, and certain cancers.
How can I study negative regulation of AIM2 inflammasome assembly?
You can use CRISPR knockout, point mutation, knock-in, overexpression models, and CRISPR library screening, combined with cytokine assays and imaging.
What are the mechanisms of negative regulation of AIM2 inflammasome assembly?
Mechanisms include autophagy-mediated degradation, ubiquitination, phosphorylation, and decoy proteins that interfere with assembly.
What is the role of autophagy in AIM2 inflammasome regulation?
Autophagy targets AIM2 and inflammasome components for lysosomal degradation, thereby inhibiting assembly.
Which proteins act as decoys to inhibit AIM2 inflammasome assembly?
POP1, CARD16, CARD17, CARD18, PYDC1, and PYDC2 are decoy proteins that inhibit AIM2 inflammasome assembly.
How does EDITGENE support research on AIM2 inflammasome negative regulation?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study negative regulators of AIM2 inflammasome assembly.
Conclusion
GO:0140972, negative regulation of AIM2 inflammasome complex assembly, is a critical biological process that maintains immune homeostasis by preventing excessive inflammation. Dysregulation of this process contributes to autoinflammatory diseases and cancer, making it an attractive target for therapeutic intervention. Advances in CRISPR-based models and screening technologies are accelerating the discovery of novel negative regulators, offering new opportunities for drug development. EDITGENE stands ready to support researchers in this endeavor with tailored CRISPR services.
References
- 1. Zouali M. 2025. Swaying the advantage: multifaceted functions of inflammasomes in adaptive immunity.. FEBS J 292(8):1817-1832 PMID: 38922787
- 2. Naik E et al.. 2010. Modulation of inflammasome activity for the treatment of auto-inflammatory disorders.. J Clin Immunol 30(4):485-90 PMID: 20358394
